Gain detailed insights into the trading activity of Congress members for CryoPort on our government trades page. Stay updated on how elected officials are investing in CYRX.

CryoPort - Government Trades

CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

airbnb shutter

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABNB

ACAD

CYRX

EXPE

LYFT

NVRO

PGNY

REAL

RIVN

TREX

TRIP

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Fortinet_logo

CRVS

DZSI

FTNT

LITM

LUMN

MYND

PRCH

SCPX

STEM

SWIM

TLIS

UPST

VBIV

XAIR

ZCMD

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Image33

APLD

ARLO

BEEM

CHPT

CLEU

CLNN

CRUS

EXFY

GNLN

HELE

HLIO

HTLD

INDV

IONM

JMIA

JNVR

KYMR

LGVN

Larimar Therapeutics, Inc. - Common Stock

LRMR

NVOS

NWTN

PATH

PEGY

Qualigen Therapeutics, Inc. - Common Stock

QLGN

QURE

RSLS

RVMD

SHPW

SNGX

SYNX

TNXP

WENA

ZAPP

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Intraday Update

BBIO

COIN

FUFU

INSP

MOLN

MSTR

NVDA

SIRI

SMCI

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

Coinbase Photo by Useacoin on Shutterstock

Price Target

AAPL

BKNG

TXRH

Coinbase Global To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Friday

Image 3

ADNT

BBAI

CTOS

OTEX

TRUP

Stem Reports Downbeat Results, Joins Sprout Social, Cloudflare And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Penny Stocks

Small Cap

HEAR

HOOD

LQDA

PERF

PLMR

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Thursday.

Build-A-Bear Workshop Reports Upbeat Earnings, Joins VAALCO Energy, Dick&#39;s Sporting Goods And Other Big Stocks Moving Higher On Thursday

Analyst Color

Equities

Downgrades

Analyst Ratings

General

KeyBanc Capital Markets analyst Paul Knight downgraded CryoPort, Inc (NASDAQ: CYRX) to 

CryoPort&#39;s Refrigeration Unit Is A Distraction From Core Business: Analyst Expects Divestiture

Earnings

Guidance

Health Care

AZTA

Cryoport Inc (NASDAQ: CYRX) shares are trading lower after the company released certain preliminary results for Q2 FY23 and updated its

Cryoport On See-Saw Of Expectations: Analysts Cut Price Targets, But Remain Bullish On Long-Term Return

Eurozone

Commodities

Global

CAMT

FWBI

JZXN

NKLA

VSAT

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Thursday.

The Dow traded up 0.15% to 34,397.80 while the NASDAQ rose 1.40% to 14,114.17. The S&amp;P 500, also rose, gaining, 0.71% to 4,504.12.

Crude Oil Rises 1.5%; PepsiCo Earnings Top Views

CryoPort Inc

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $11 price target.

Reiteration

Needham Reiterates Buy on CryoPort, Maintains $11 Price Target

Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services
TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4339690-1&amp;h=4120392140&amp;u=https%3A%2F%2Fus-west-2.protection.sophos.com%2F%3Fd%3Dmoffitt.org%26u%3DaHR0cDovL3d3dy5tb2ZmaXR0Lm9yZy8%3D%26i%3DNjNmZDA0M2Y1ZmU5MWU0NzZhZmE4N2Zl%26t%3DaUZRYU1XWkVOVDB0V3VuVktEMnJoQ0ZvOTBVZDc3OW9iVk9rQUZHblp3RT0%3D%26h%3Daefc28a124854e57b0d7e4aa146b700f%26s%3DAVNPUEhUT0NFTkNSWVBUSVbZZKR4Dy8LAnIFXi4oHjrnHjjtX3iIDJXdjFVuaI3Hpg&amp;a=Moffitt+Cancer+Center">Moffitt Cancer Center</a>, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4339690-1&amp;h=3012007002&amp;u=https%3A%2F%2Fus-west-2.protection.sophos.com%2F%3Fd%3Dsperosfl.org%26u%3DaHR0cDovL3NwZXJvc2ZsLm9yZy8%3D%26i%3DNjNmZDA0M2Y1ZmU5MWU0NzZhZmE4N2Zl%26t%3DRnI0QkVOdVZkZmFLbmZZcDQxU1hKNFRyWnRTdGVRb2dFaEQ2aHVkckFSVT0%3D%26h%3Daefc28a124854e57b0d7e4aa146b700f%26s%3DAVNPUEhUT0NFTkNSWVBUSVbZZKR4Dy8LAnIFXi4oHjrnHjjtX3iIDJXdjFVuaI3Hpg&amp;a=Speros+FL">Speros FL</a>, a 775-acre global innovation life sciences campus, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4339690-1&amp;h=227070225&amp;u=http%3A%2F%2Fwww.cryoportinc.com%2F&amp;a=Cryoport%2C+Inc.">Cryoport, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4339690-1&amp;h=550582053&amp;u=https%3A%2F%2Fcryogenelab.com%2F&amp;a=CRYOGENE">CRYOGENE</a>'s state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that is focused on the secure storage of biological specimens and associated services.

Biotech

Cryoport's CRYOGENE To Provide State-Of-The-Art Biorepository Services To Moffitt Cancer Center Via Strategic Collaboration

All Three MVE Biological Solutions' Manufacturing&nbsp;Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed

Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities With FDA

Roth MKM analyst Richard Baldry maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $18 to $15.

Roth MKM Maintains Buy on CryoPort, Lowers Price Target to $15

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.31) by 93.55 percent. The company reported quarterly sales of $56.664 million which missed the analyst consensus estimate of $58.042 million by 2.37 percent. This is a 0.90 percent increase over sales of $56.157 million the same period last year.

Earnings Beats

Earnings Misses

CryoPort Q3 2024 GAAP EPS $(0.02) Beats $(0.31) Estimate, Sales $56.664M Miss $58.042M Estimate

Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell&#x2122;&nbsp;Houston Facility
NASHVILLE, Tenn. and HOUSTON, Oct. 22, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4283560-1&amp;h=1582915588&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc.">Cryoport, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4283560-1&amp;h=2818938700&amp;u=https%3A%2F%2Fwww.giveblood.org%2F&amp;a=Gulf+Coast+Regional+Blood+Center">Gulf Coast Regional Blood Center</a> ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment.
The launch of this partnership coincides with the grand opening of Cryoport's new state-of-the-art IntegriCell&#x2122; facility located at Cryoport's integrated supply chain campus in Houston, Texas.
This collaboration brings together GCRBC's Cellular Life Solutions ("CLS") program, which specializes in allogeneic donor recruitment, management, and apheresis collection, with Cryoport's industry-leading cryopreservation and biologistics expertise, creating a comprehensive and unified service offering for the life sciences community. GCRBC's CLS program is located less than two miles from Cryoport's Houston campus, enabling efficient local transport of collected leukopaks through Cryoport's Cryoshuttle&#xAE;&nbsp;transportation service.

Cryoport And Gulf Coast Regional Blood Center Announce A Strategic Alliance To Enhance The Availability Of High-Quality, Manufacture-Ready Cryopreserved Allogeneic Leukopaks For Cellular Therapy Research, Development, And Treatment.

Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted&nbsp; Solutions for Secure IVF Specimen Management and Transport

TMRW Life Sciences And CryoPort Systems Form Strategic Partnership To Improve Standards For Frozen Egg, Embryo, And Sperm Offsite Storage And Biologistics

In the latest quarter, 5 analysts provided ratings for CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CryoPort and provided 12-month price targets. The average target is $10.0, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 38.27% decline, the current average is now lower than the previous average price target of $16.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1729263648_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yuan Zhi</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CryoPort. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CryoPort's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, CryoPort showcased positive performance, achieving a revenue growth rate of 1.01% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -138.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -19.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): CryoPort's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.91%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CryoPort's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.09, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring CryoPort Through Analyst Insights

UBS analyst Dan Leonard maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and raises the price target from $7 to $9.

UBS Maintains Neutral on CryoPort, Raises Price Target to $9

The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies

Cryoport Launches IntegriCell Cryopreservation Solution; Open Facility At Houston Campus

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.25, with a high estimate of $15.00 and a low estimate of $7.00. This current average has decreased by 44.59% from the previous average price target of $18.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1723057748_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of CryoPort by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yuan Zhi</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CryoPort's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering CryoPort: A Closer Look</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Understanding the Numbers: CryoPort's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, CryoPort faced challenges, resulting in a decline of approximately -13.09% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CryoPort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -38.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's ROE excels beyond industry benchmarks, reaching -4.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.2%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From CryoPort Analyst Ratings

UBS analyst Dan Leonard maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and lowers the price target from $17 to $7.

UBS Maintains Neutral on CryoPort, Lowers Price Target to $7

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
Shares of Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) dipped 15.8% to $109.68 after the company reported worse-than-expected second-quarter EPS results and issued third-quarter revenue <a href="https://www.benzinga.com/markets/equities/24/08/40213199/why-airbnb-stock-is-down-16-in-wednesday-pre-market">guidance below estimates</a>.
Airbnb's second-quarter sales of $2.748 billion exceeded the analyst consensus estimate of $2.738 billion, marking a 10.63% increase from the same period last year. However, the company's quarterly GAAP earnings of 86 cents per share fell short of the analyst consensus estimate of 92 cents, missing the mark by 6.52%.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares dipped 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares declined 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) dipped 24.8% to $10.50 in pre-market trading following weak quarterly sales.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares slipped 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) dipped 19.4% to $2.50 in pre-market trading following second-quarter results.</li>
<li>Trex Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) fell 16.7% to $63.75 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) dipped 16.7% to $15.70 following second-quarter results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) fell 16.5% to $21.48 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 15.4% to $13.80 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares declined 14.2% to $9.41 following second-quarter financial results.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) dipped 8.1% to $13.60 after the company reported worse-than-expected quarterly adjusted EPS results.</li>
<li>Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) dipped 6.2% to $84.78 following weak quarterly sales.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell 3.8% to $113.05.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jefferies analyst Matthew Stanton downgrades CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) from Buy to Hold and lowers the price target from $20 to $8.

Jefferies Downgrades CryoPort to Hold, Lowers Price Target to $8

CryoPort shares are trading lower after the company reported mixed Q2 financial results and issued FY24 revenue guidance below estimates. Also, Needham maintained a Buy rating on the stock and lowered its price target from $18 to $11.

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Needham analyst David Saxon maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $18 to $11.

Needham Maintains Buy on CryoPort, Lowers Price Target to $11

Cryport Sees FY24 Revenue $225M-$235M Vs $240.513M Est.

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.39) by 25.64 percent. The company reported quarterly sales of $57.597 million which missed the analyst consensus estimate of $57.684 million by 0.15 percent. This is a 1.01 percent increase over sales of $57.021 million the same period last year.

CryoPort Q2 2024 Adj. EPS $(0.29) Beats $(0.39) Estimate, Sales $57.597M Miss $57.684M Estimate

Press Releases

Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus

VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies

Contracts

TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics

Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services

Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024

Cryoport Reports Third Quarter 2024 Financial Results

Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe

Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")

Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies

Needham

Roth MKM

Jefferies

B. Riley Securities


Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Sale	Oct 15, 2023	Sep 15, 2023	House
Donald BeyerHouse (D-VA)	$1K - $15K	stock	Sale	Mar 03, 2022	Feb 28, 2022	House

Government Trades

CryoPort Inc

top performing CYRX trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga